Azitra reports Q2 2026 results, pauses Netherton syndrome enrollment

Azitra, Inc. reported financial results for the quarter ended June 30, 2026 on August 12, 2026, alongside a business update covering its dermatology and biotechnology pipeline.

The company said it generated initial preclinical findings from ATR-COSF showing repeat-dose distribution into targeted skin layers along with anti-wrinkle effects in ex vivo human skin, supporting plans to move toward a proof-of-concept clinical study.¹ A human cosmetic application study is planned to start in the third quarter of 2026.¹

For ATR-04, its investigational therapy for EGFR inhibitor-associated rash, Azitra said it continued enrolling the first cohort of the Phase 1/2 trial.¹ The trial has six active clinical sites, including MD Anderson Cancer Center, and the company said it remains on track to report topline data from the first cohort around year end.¹ Azitra also said it is working to broaden eligibility to include other rashes tied to cancer treatments that act on the related EGFR, KRAS, MEK and ERK signaling pathway.¹

The company also disclosed a pipeline change: it plans to strategically pause further enrollment in the ongoing Phase 1b study evaluating ATR-12 for Netherton syndrome.¹ Azitra attributed the decision to a more selective allocation of capital toward programs it views as having the strongest near-term potential for clinical, commercial and shareholder value.¹

Separately, Azitra said it continued advancing recombinant protein programs, including Tobacco Etch Virus (TEV) Protease and T7 RNA Polymerase, as it expands into biotechnology research and manufacturing applications.¹

On finances, the company reported cash and cash equivalents of $6.7 million as of June 30, 2026.¹ Net loss for the quarter was $3.3 million, compared with $2.9 million in the same period of 2025.¹